Sichuan Kelun-Biotech Receives Upfront Payment in License Agreement with Windward Bio

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H ( (HK:6990) ) has issued an announcement.

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. announced the receipt of an upfront payment from Windward Bio AG as part of their exclusive license agreement for SKB378/HBM9378/WIN378. This payment includes both cash and equity interests, marking a significant step in the co-development of a novel monoclonal antibody targeting the TSLP ligand, which is crucial in managing immunological conditions. The IND application for this treatment has been approved by the NMPA, and phase 1 clinical trials have been completed, with phase 2 trials being prepared by Windward Bio.

The most recent analyst rating on (HK:6990) stock is a Buy with a HK$300.00 price target. To see the full list of analyst forecasts on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H stock, see the HK:6990 Stock Forecast page.

More about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a biopharmaceutical company based in China, focusing on the development of innovative therapeutics, particularly in the field of monoclonal antibodies for treating immunological conditions such as asthma and COPD.

Average Trading Volume: 703,468

Technical Sentiment Signal: Buy

Current Market Cap: HK$74.32B

For an in-depth examination of 6990 stock, go to TipRanks’ Stock Analysis page.